Dr Hsu reports institutional support from the Health Resources and Services Administration, the National Institutes of Health, the European Commission, the Illinois Department of Public Health, the Joy in Childhood Foundation, Global Blood Therapeutics, Forma Therapeutics, Imara, Baxalta, Cyclerion, and Eli Lilly; consulting fees from DuPont Nemours Children’s Hospital, Hoffman-LaRoche, DisperSol, Guidepoint, Magellan, Deerfield, and Kuwait University; speaker honoraria from the Foundation for Sickle Cell Disease Research, Bridgeport Hospital, and Tova Health Center; participation on an Aruvant Data Safety Monitoring Board and service as a scientific advisor or member of an expert advisory board for the National Institutes of Health Sickle Cell Disease Advisory Committee, Hilton Publishing/HPC, and the Illinois Universal Newborn Screening Advisory Committee; and unpaid membership in the Sickle Cell Disease Association of America, the Sickle Cell Disease Association of Illinois, and the National Alliance of Sickle Cell Centers. All other authors have indicated they have no conflicts of interest relevant to this article to disclose.